Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02294227) enrolled 341 people in total — 114 received secukinumab 150 mg with a loading dose schedule, 113 received secukinumab 150 mg without a loading dose, and 114 received a placebo (an inactive treatment). The trial was measuring responses in people with psoriatic arthritis, looking at things like joint swelling and tenderness, skin involvement, and quality of life over 16 weeks. By the end of the study, 89, 88, and 95 participants had completed the study in each group respectively. The reported data shows that for the main outcome — the number of people who achieved at least a 20% improvement in joint swelling, tenderness, and related measures (called an "ACR20 response") — 47 out of 114 participants in the secukinumab loading-dose group, 45 out of 113 in the no-loading-dose group, and 21 out of 114 in the placebo group met this threshold at Week 16. For a higher bar of at least 50% improvement (ACR50), the reported numbers were 26, 19, and 7 participants respectively. The reported data also shows that a skin severity score measuring psoriasis coverage and intensity (PASI75, meaning at least a 75% improvement in that score) was reached by 29, 27, and 5 participants across the three groups. A general disease activity score (rated on a scale where higher numbers mean more severe disease) changed by −0.98, −0.84, and −0.21 points from the start of the study in each group. A quality-of-life physical score (where higher numbers indicate better physical wellbeing, out of 100) changed by +3.42, +3.44, and +0.63 points respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38446397) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Psoriatic Arthritis (a condition causing joint pain and skin symptoms) using a specific set of recognised diagnostic guidelines.
- Certain blood tests (Rheumatoid factor and anti-CCP antibodies) have come back negative.
- You have active plaque psoriasis (a skin condition causing scaly, red patches) or nail changes linked to psoriasis.
- Your symptoms have not been well controlled by anti-inflammatory painkillers (such as ibuprofen or naproxen).
- There may be additional eligibility requirements set by the trial team (confirm with trial site).
Who may not be able to join:
- Your chest X-ray or chest MRI scan shows signs of an active infection or possible cancer.
- You are currently taking strong opioid painkillers (such as morphine or oxycodone).
- You have previously taken a medication called secukinumab, or any similar biological drug that targets a specific part of the immune system known as IL-17 or its receptor.
- You are currently using certain treatments or medications for psoriasis that are not allowed in this trial (confirm with trial site for the specific list).
- You have ever received certain types of biological medicines that affect the immune system, with the exception of those targeting a protein called TNFα.
- You have previously had any treatment designed to remove or reduce specific immune cells from your body.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With American College of Rheumatology 20 (ACR20) Response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.